Belgian biopharmaceutical company Cardio3 Biosciences, which is backed by a consortium of venture capital firms, has announced that it is considering listing new shares in an IPO.
The company, which raised €19m last month from existing investors in the form of €7m in fresh equity and €12m as a conversion of convertible loans, hopes to raise new funds through an IPO on NYSE...
Catch up on essential features from this past week with our round-up of industry analysis
Keensight's participation marks the first external investment in the group since inception
Capiton exits the business to the American investor after following a buy-and-build strategy
British mattress manufacturer will look to expand internationally